Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15071)	2/14/1998 1:09:00 PM
From: Andrew H	Read Replies (4) \| Respond to of 32384

While it is a long way from rats to people (despite Bernie's apparent predilections), one would think the recent news would have been good for more than a skimpy one point jump. If tamoxifen pulls in 560MM a year, then it is not much of a leap to envision LGND's revenues going up substantially when Targretin comes to market in the first part of 1999. Of course it depends on preliminary P2 results, but these ought to be available by the time Targretin gets FDA approval. My guess is that they will start a couple of trials very soon--Targretin as monotherapy and Targretin in combination with Tamoxifen. Good results for either will result in a lot of off label prescriptions for Targretin, IMO. If this scenario pans out, LGND could earn a LOT more than .09/share in 1999.